---
title: "Weekly Recap | INNOVENT BIO -4.53%, most brokers rate it buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306350411.md"
description: "INNOVENT BIO closed the week at HK$80.10, down 4.53% over the four trading sessions. The Hang Seng Index fell 5.65%, meaning the stock outperformed the benchmark by roughly 1.12 percentage points. The week opened at HK$83.90 on Monday, spiked to an intraday high of HK$86.55, then drifted lower over the following sessions. Thursday saw a low of HK$79.40 before a modest rebound to settle above HK$80, leaving a pattern of early strength followed by a pullback."
datetime: "2026-11-21T05:14:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306350411.md)
  - [en](https://longbridge.com/en/news/306350411.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306350411.md)
generator: "portal-rs"
---

# Weekly Recap | INNOVENT BIO -4.53%, most brokers rate it buy

## The Week

INNOVENT BIO (1801.HK) closed the week at HK$80.10, down 4.53% over the four trading sessions. The Hang Seng Index fell 5.65%, meaning the stock outperformed the benchmark by roughly 1.12 percentage points. The week opened at HK$83.90 on Monday, spiked to an intraday high of HK$86.55, then drifted lower over the following sessions. Thursday saw a low of HK$79.40 before a modest rebound to settle above HK$80, leaving a pattern of early strength followed by a pullback. Weekly amplitude came to 8.52%, with average daily volume about 8.6% above the recent median.

## Key Events

The week’s narrative centred on European regulatory progress for Zybrivo (sintilimab) and the acquisition of partner Ollin Biosciences by Johnson & Johnson. On Monday morning, Innovent announced that Zybrivo had received a positive CHMP opinion, recommending approval for first-line treatment of non-squamous non-small cell lung cancer. That evening, partner Ollin revealed it had entered an agreement to be acquired by J&J. Ollin focuses on next-generation medicines for vision-threatening eye diseases; the deal does not change Innovent’s equity stake, but several brokers read it as validation of the company’s ophthalmology R&D. UBS made that point on Tuesday, and HSBC Research followed on Friday by raising its target price to HK$133. On the industry front, China added a record 51 innovative drugs to the public medical insurance catalog, with Citi noting that drugmakers described the price cuts as mild and manageable.

## Analyst Ratings

As of this week, 28 brokers cover INNOVENT BIO. Of these, 19 rate it a buy, 7 rate it overweight, and 2 rate it hold; none rate it underweight or sell. The consensus recommendation is strong buy, with a consensus target price of about HK$131.0, implying roughly 63.5% upside from the spot price of HK$80.10. Individual target prices range from HK$94.96 to HK$157.16, a wide spread that points to meaningful disagreement about the longer-term valuation. Within the biotechnology industry, the stock ranks 1st out of 52 companies on analyst ratings.

## The Week Ahead

Innovent is scheduled to release its fiscal Q3 2026 results after market close on Wednesday, 25 November. That is the most direct near-term catalyst. The week’s developments—the positive CHMP opinion for Zybrivo, the J&J acquisition of Ollin, and the conclusion of the 2026 NRDL negotiations—provide fresh context for the company’s overseas commercialisation prospects and the broader pricing environment in China. The earnings release will test whether these catalysts are beginning to translate into financial improvement, with revenue momentum and R&D spending trends likely to draw attention. Separately, the sharp sell-off in Hong Kong tech stocks late in the week, which dragged the Hang Seng down more than 2% in a single session, raises the question of whether that volatility will spill into the biopharma space next week.

## In Short

INNOVENT BIO enters the end of the week with conflicting signals. The ratings backdrop is clearly supportive: 26 of 28 brokers assign a buy or overweight rating, consensus sits at strong buy, and the consensus target is more than 60% above spot. Valuation reflects high expectations, with a price-to-book ratio around 5.9x and a trailing price-to-earnings ratio near 99x. Yet the stock still finished the week lower after an early rally, and the latest single-day capital flow shows both large-lot buying and selling without a clear directional lean, suggesting divided near-term conviction among traders. The key question now is whether next week’s quarterly results can provide firmer financial grounding for that valuation and consensus view, and how much Hong Kong’s broader volatility feeds into biotech risk appetite.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [01801.HK](https://longbridge.com/en/quote/01801.HK.md)

## Related News & Research

- [Innovent adds seven products to China’s 2026 NRDL](https://longbridge.com/en/news/305580225.md)
- [UBS: Johnson & Johnson's Acquisition of Ollin Validates INNOVENT BIO  Ophthalmology R&D](https://longbridge.com/en/news/305767362.md)
- [Innovent's Zybrivo Receives Positive CHMP Opinion for First-Line Lung Cancer Treatment](https://longbridge.com/en/news/305586235.md)
- [Innovent Announces Seven Innovative Products Including Mazdutide and PECONDLE® Successfully Included in the 2026 National Reimbursement Drug List](https://longbridge.com/en/news/305522173.md)
- [Innovent Biologics reports 1H results](https://longbridge.com/en/news/296950734.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**